CRP in cardiovascular disease

Herz

Volumn 34, Issue 8, 2009, Pages 607-613

  Karakas, Mahir ^a   Koenig, Wolfgang ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Atherosclerosis; Biomarker; C reactive protein; Inflammation; JUPITER; Predictive value

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CYSTATIN C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; TROPONIN I;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTERY DISEASE; ATHEROGENESIS; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DISEASE MARKER; FOLLOW UP; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HIGH RISK POPULATION; HORMONAL THERAPY; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; INFLAMMATION; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MORTALITY; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION AND FORECASTING; PREDICTOR VARIABLE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PUBLIC HEALTH SERVICE; REVASCULARIZATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STROKE; SUDDEN DEATH; SYSTEMATIC REVIEW; UNSTABLE ANGINA PECTORIS;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; ECHOCARDIOGRAPHY; HUMANS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 73649109554     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-009-3305-7     Document Type: Review

References (26)

1. C. Arnaud F. Burger S. Steffens, et al. 2005 Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct anti-inflammatory effects of statins Arterioscler Thromb Vasc Biol 25 1231 1236 10.1161/01.ATV.0000163840.63685.0c 1:CAS:528:DC%2BD2MXksVWqsb4%3D 15790934 (Pubitemid 40776614)
2. J. Danesh J.G. Wheeler G.M. Hirschfield, et al. 2004 C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease N Engl J Med 350 1387 1397 10.1056/NEJMoa032804 1:CAS:528:DC%2BD2cXivVagsbc%3D 15070788 (Pubitemid 38419992)
3. P. Elliott J.C. Chambless W. Zhang, et al. 2009 Genetic loci associated with C-reactive protein levels and risk of coronary heart disease JAMA 302 37 48 10.1001/jama.2009.954 1:CAS:528:DC%2BD1MXotFKns78%3D 19567438
4. E.S. Ford G. Zhao A.H. Mokdad 2009 Concentrations of low-density lipoprotein cholesterol and total cholesterol among children and adolescents in the United States Circulation 119 1108 1115 10.1161/CIRCULATIONAHA.108.816769 1:CAS:528:DC%2BD1MXitF2js7o%3D 19221218
5. R.J. Glynn E. Danielson, et al. 2009 A randomized trial in the prevention of venous thromboembolism N Engl J Med 360 1851 1861 10.1056/NEJMoa0900241 1:CAS:528:DC%2BD1MXlsVSlurk%3D 19329822
6. M.A. Hlatky P. Greenland D.K. Arnett, et al. 2009 Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association Circulation 119 2408 2416 10.1161/CIRCULATIONAHA.109. 192278 19364974
7. I. Jialal S. Devaraj S.K. Venugopal 2004 C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 44 6 11 10.1161/01.HYP.0000130484. 20501.df 1:CAS:528:DC%2BD2cXltVSqt7w%3D 15148294 (Pubitemid 38823477)
8. M. Karakas M.M. Hoffmann C. Vollmert, et al. 2009 Genetic variation in Fc gamma receptor IIa and risk of coronary heart disease: negative results from two large independent populations BMC Med Genet 10 46 10.1186/1471-2350-10-46 19480687
9. W. Koenig 2005 Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein Int J Cardiol 98 199 206 10.1016/j.ijcard.2004. 05.019 15686768 (Pubitemid 40431164)
10. W. Koenig 2009 Is hsCRP back on board? Implications from the JUPITER trial Clin Chem 55 216 218 10.1373/clinchem.2008.115915 1:CAS:528: DC%2BD1MXhvVWksrY%3D 19074517
11. W. Koenig N. Khuseyinova 2007 Biomarkers of atherosclerotic plaque instability and rupture Arterioscler Thromb Vasc Biol 27 15 26 10.1161/01.ATV.0000251503.35795.4f 1:CAS:528:DC%2BD28XhtlSrsb7I 17082488 (Pubitemid 46360377)
12. W. Koenig H. Löwel J. Baumert, et al. 2004 C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany Circulation 109 1349 1353 10.1161/01.CIR.0000120707.98922.E3 15023871 (Pubitemid 38387819)
13. W. Koenig M. Sund M. Fröhlich, et al. 1999 C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992 Circulation 99 237 242 1:STN:280:DyaK1M7htVOhtQ%3D%3D 9892589
14. P. Libby 2002 Inflammation in atherosclerosis Nature 420 868 874 10.1038/nature01323 1:CAS:528:DC%2BD38XpsFygtb8%3D 12490960 (Pubitemid 36019640)
15. G. Liuzzo L.M. Biasucci J.R. Gallimore, et al. 1994 The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina N Engl J Med 331 417 424 10.1056/NEJM199408183310701 1:STN:280: DyaK2czgvFKruw%3D%3D 7880233 (Pubitemid 24247397)
16. O. Melander C. Newton-Chec P. Almgren, et al. 2009 Novel and conventional biomarkers for prediction of incident cardiovascular events in the community JAMA 302 49 57 10.1001/jama.2009.943 1:CAS:528:DC%2BD1MXotFKns7o%3D 19567439
17. S. Mora K. Musunuru R.S. Blumenthal 2009 The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines Clin Chem 55 219 228 10.1373/clinchem.2008.109728 1:CAS:528:DC%2BD1MXhvVWksrc%3D 19095730
18. K. Musunuru B.G. Kral R.S. Blumenthal, et al. 2008 The use of high-sensitivity assays for C-reactive protein in clinical practice Nat Clin Pract Cardiovasc Med 5 621 635 10.1038/ncpcardio1322 1:CAS:528: DC%2BD1cXhtFGhs73O 18711404
19. NACB LMPG Committee Members Myers GL Christenson RH Cushman M 2009 National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease Clin Chem 55 378 384 10.1373/clinchem.2008.115899
20. P.M. Ridker 2009 The JUPITER trial: results, controversies, and implications for prevention Circ Cardiovasc Qual Outcomes 2 279 285 10.1161/CIRCOUTCOMES.109.868299
21. P.M. Ridker E. Danielson F. Fonseca, et al. 2008 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2195 2207 10.1056/NEJMoa0807646 1:CAS:528:DC%2BD1cXhtl2gurnL 18997196
22. P.M. Ridker E. Danielson F. Fonseca, et al. 2009 Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet 373 1175 1182 10.1016/S0140-6736(09)60447-5 1:CAS:528:DC%2BD1MXktV2gsL8%3D 19329177
23. P.M. Ridker N. Rifai M. Clearfield, et al. 2001 Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N Engl J Med 344 1959 1965 10.1056/NEJM200106283442601 1:CAS:528:DC%2BD3MXltFersrc%3D 11430324 (Pubitemid 32568149)
24. E.S. Spatz M.E. Canavan M.M. Desai 2009 From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey Circ Cardiovasc Qual Outcomes 2 41 48 10.1161/CIRCOUTCOMES.108.832592
25. J. Zacho A. Tybjaerg-Hansen J.S. Jensen, et al. 2008 Genetically elevated C-reactive protein and ischemic vascular disease N Engl J Med 359 1897 1908 10.1056/NEJMoa0707402 1:CAS:528:DC%2BD1cXhtlaitbbE 18971492
26. B. Zethelius L. Berglund J. Sundström, et al. 2008 Use of multiple biomarkers to improve the prediction of death from cardiovascular causes N Engl J Med 358 2107 2116 10.1056/NEJMoa0707064 1:CAS:528:DC%2BD1cXlvFCrsrw%3D 18480203 (Pubitemid 351679597)